Insider Transactions in Q1 2024 at Ani Pharmaceuticals Inc (ANIP)
Insider Transaction List (Q1 2024)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 23
2024
|
Stephen P. Carey SVP & CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
6,210
-3.49%
|
$428,490
$69.58 P/Share
|
|
Mar 23
2024
|
Nikhil Lalwani PRESIDENT & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
17,455
-4.24%
|
$1,204,395
$69.58 P/Share
|
|
Mar 23
2024
|
James G. Marken SVP OPS & PROD DEV |
SELL
Payment of exercise price or tax liability
|
Direct |
3,653
-2.98%
|
$252,057
$69.58 P/Share
|
|
Mar 13
2024
|
Meredith Cook SR. VP, GENERAL COUNSEL & SEC. |
SELL
Open market or private sale
|
Direct |
250
-0.42%
|
$16,500
$66.54 P/Share
|
|
Mar 11
2024
|
Chad Gassert SVP - CORP. DEV. & STRATEGY |
SELL
Open market or private sale
|
Indirect |
20,000
-6.82%
|
$1,300,000
$65.81 P/Share
|
|
Mar 11
2024
|
Stephen P. Carey SVP & CFO |
SELL
Open market or private sale
|
Direct |
7,787
-4.2%
|
$506,155
$65.55 P/Share
|
|
Mar 08
2024
|
Muthusamy Shanmugam HEAD OF R&D, COO-NOVITIUM OPS |
SELL
Open market or private sale
|
Indirect |
10,000
-1.19%
|
$670,000
$67.17 P/Share
|
|
Mar 08
2024
|
Nikhil Lalwani PRESIDENT & CEO |
SELL
Open market or private sale
|
Direct |
16,292
-3.81%
|
$1,091,564
$67.13 P/Share
|
|
Mar 07
2024
|
Stephen P. Carey SVP & CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
4,216
-2.22%
|
$278,256
$66.71 P/Share
|
|
Mar 07
2024
|
Nikhil Lalwani PRESIDENT & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
17,060
-3.83%
|
$1,125,960
$66.71 P/Share
|
|
Mar 07
2024
|
James G. Marken SVP OPS & PROD DEV |
SELL
Payment of exercise price or tax liability
|
Direct |
2,034
-1.63%
|
$134,244
$66.71 P/Share
|
|
Mar 07
2024
|
James G. Marken SVP OPS & PROD DEV |
SELL
Open market or private sale
|
Direct |
24,338
-16.35%
|
$1,606,308
$66.37 P/Share
|
|
Mar 07
2024
|
Ori Gutwerg SVP, GENERICS |
SELL
Payment of exercise price or tax liability
|
Direct |
2,494
-3.02%
|
$164,604
$66.71 P/Share
|
|
Mar 07
2024
|
Christopher Mutz HEAD OF RARE DISEASE |
SELL
Payment of exercise price or tax liability
|
Direct |
2,110
-2.41%
|
$139,260
$66.71 P/Share
|
|
Mar 07
2024
|
Muthusamy Shanmugam HEAD OF R&D, COO-NOVITIUM OPS |
SELL
Open market or private sale
|
Indirect |
15,085
-1.76%
|
$995,610
$66.35 P/Share
|
|
Mar 06
2024
|
Nikhil Lalwani PRESIDENT & CEO |
SELL
Open market or private sale
|
Direct |
28,965
-6.11%
|
$1,882,725
$65.52 P/Share
|
|
Mar 06
2024
|
Muthusamy Shanmugam HEAD OF R&D, COO-NOVITIUM OPS |
SELL
Open market or private sale
|
Indirect |
14,822
-1.7%
|
$963,430
$65.47 P/Share
|
|
Mar 05
2024
|
Muthusamy Shanmugam HEAD OF R&D, COO-NOVITIUM OPS |
SELL
Open market or private sale
|
Indirect |
10,093
-1.14%
|
$656,045
$65.35 P/Share
|
|
Mar 05
2024
|
Christopher Mutz HEAD OF RARE DISEASE |
SELL
Open market or private sale
|
Direct |
5,000
-5.41%
|
$330,000
$66.0 P/Share
|
|
Mar 04
2024
|
Antonio R Pera Director |
SELL
Open market or private sale
|
Direct |
7,000
-20.82%
|
$455,000
$65.2 P/Share
|
|
Feb 29
2024
|
Muthusamy Shanmugam HEAD OF R&D, COO-NOVITIUM OPS |
SELL
Payment of exercise price or tax liability
|
Direct |
1,122
-1.61%
|
$75,174
$67.67 P/Share
|
|
Feb 29
2024
|
Christopher Mutz HEAD OF RARE DISEASE |
SELL
Payment of exercise price or tax liability
|
Direct |
1,275
-1.36%
|
$85,425
$67.67 P/Share
|
|
Feb 29
2024
|
Nikhil Lalwani PRESIDENT & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
10,014
-2.07%
|
$670,938
$67.67 P/Share
|
|
Feb 29
2024
|
James G. Marken SVP OPS & PROD DEV |
SELL
Payment of exercise price or tax liability
|
Direct |
1,058
-0.71%
|
$70,886
$67.67 P/Share
|
|
Feb 29
2024
|
Krista Davis SVP, CHIEF HR OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
1,173
-2.23%
|
$78,591
$67.67 P/Share
|
|
Feb 29
2024
|
Chad Gassert SVP - CORP. DEV. & STRATEGY |
SELL
Payment of exercise price or tax liability
|
Direct |
1,635
-3.19%
|
$109,545
$67.67 P/Share
|
|
Feb 29
2024
|
Ori Gutwerg SVP, GENERICS |
SELL
Payment of exercise price or tax liability
|
Direct |
1,570
-1.86%
|
$105,190
$67.67 P/Share
|
|
Feb 29
2024
|
Stephen P. Carey SVP & CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,914
-1.0%
|
$128,238
$67.67 P/Share
|
|
Feb 29
2024
|
Meredith Cook SR. VP, GENERAL COUNSEL & SEC. |
SELL
Payment of exercise price or tax liability
|
Direct |
1,173
-1.91%
|
$78,591
$67.67 P/Share
|
|
Feb 15
2024
|
Ori Gutwerg SVP, GENERICS |
SELL
Payment of exercise price or tax liability
|
Direct |
1,244
-1.45%
|
$70,908
$57.55 P/Share
|
|
Feb 15
2024
|
Christopher Mutz HEAD OF RARE DISEASE |
SELL
Payment of exercise price or tax liability
|
Direct |
1,261
-1.33%
|
$71,877
$57.55 P/Share
|
|
Feb 14
2024
|
Nikhil Lalwani PRESIDENT & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
134,216
+12.88%
|
-
|
|
Feb 14
2024
|
Christopher Mutz HEAD OF RARE DISEASE |
BUY
Grant, award, or other acquisition
|
Direct |
31,316
+15.11%
|
-
|
|
Feb 14
2024
|
Muthusamy Shanmugam HEAD OF R&D, COO-NOVITIUM OPS |
BUY
Grant, award, or other acquisition
|
Direct |
22,367
+14.72%
|
-
|
|
Feb 14
2024
|
James G. Marken SVP OPS & PROD DEV |
BUY
Grant, award, or other acquisition
|
Direct |
16,776
+5.43%
|
-
|
|
Feb 14
2024
|
Chad Gassert SVP - CORP. DEV. & STRATEGY |
BUY
Grant, award, or other acquisition
|
Direct |
22,367
+19.45%
|
-
|
|
Feb 14
2024
|
Ori Gutwerg SVP, GENERICS |
BUY
Grant, award, or other acquisition
|
Direct |
24,605
+13.32%
|
-
|
|
Feb 14
2024
|
Krista Davis SVP, CHIEF HR OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
20,131
+17.27%
|
-
|
|
Feb 14
2024
|
Stephen P. Carey SVP & CFO |
BUY
Grant, award, or other acquisition
|
Direct |
35,790
+8.88%
|
-
|
|
Feb 14
2024
|
Meredith Cook SR. VP, GENERAL COUNSEL & SEC. |
BUY
Grant, award, or other acquisition
|
Direct |
24,605
+18.04%
|
-
|
|
Feb 13
2024
|
Meredith Cook SR. VP, GENERAL COUNSEL & SEC. |
SELL
Open market or private sale
|
Direct |
250
-0.67%
|
$14,000
$56.04 P/Share
|
|
Jan 23
2024
|
Muthusamy Shanmugam HEAD OF R&D, COO-NOVITIUM OPS |
SELL
Open market or private sale
|
Indirect |
15,000
-1.67%
|
$840,000
$56.44 P/Share
|
|
Jan 22
2024
|
Muthusamy Shanmugam HEAD OF R&D, COO-NOVITIUM OPS |
SELL
Open market or private sale
|
Indirect |
5,692
-0.63%
|
$313,060
$55.95 P/Share
|
|
Jan 19
2024
|
Muthusamy Shanmugam HEAD OF R&D, COO-NOVITIUM OPS |
SELL
Open market or private sale
|
Indirect |
4,524
-0.5%
|
$248,820
$55.57 P/Share
|
|
Jan 18
2024
|
Muthusamy Shanmugam HEAD OF R&D, COO-NOVITIUM OPS |
SELL
Open market or private sale
|
Indirect |
9,784
-1.07%
|
$538,120
$55.3 P/Share
|
|
Jan 17
2024
|
Muthusamy Shanmugam HEAD OF R&D, COO-NOVITIUM OPS |
SELL
Open market or private sale
|
Indirect |
10,000
-1.08%
|
$550,000
$55.11 P/Share
|
|
Jan 16
2024
|
Muthusamy Shanmugam HEAD OF R&D, COO-NOVITIUM OPS |
SELL
Open market or private sale
|
Indirect |
5,000
-0.54%
|
$275,000
$55.63 P/Share
|
|
Jan 12
2024
|
Meredith Cook SR. VP, GENERAL COUNSEL & SEC. |
SELL
Open market or private sale
|
Direct |
250
-0.67%
|
$14,000
$56.43 P/Share
|